1. Home
  2. NTLA vs AMRC Comparison

NTLA vs AMRC Comparison

Compare NTLA & AMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • AMRC
  • Stock Information
  • Founded
  • NTLA 2014
  • AMRC 2000
  • Country
  • NTLA United States
  • AMRC United States
  • Employees
  • NTLA N/A
  • AMRC N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • AMRC Engineering & Construction
  • Sector
  • NTLA Health Care
  • AMRC Consumer Discretionary
  • Exchange
  • NTLA Nasdaq
  • AMRC Nasdaq
  • Market Cap
  • NTLA 1.2B
  • AMRC 1.3B
  • IPO Year
  • NTLA 2016
  • AMRC 2010
  • Fundamental
  • Price
  • NTLA $25.74
  • AMRC $39.53
  • Analyst Decision
  • NTLA Buy
  • AMRC Buy
  • Analyst Count
  • NTLA 19
  • AMRC 8
  • Target Price
  • NTLA $30.47
  • AMRC $25.50
  • AVG Volume (30 Days)
  • NTLA 7.7M
  • AMRC 754.9K
  • Earning Date
  • NTLA 11-06-2025
  • AMRC 11-03-2025
  • Dividend Yield
  • NTLA N/A
  • AMRC N/A
  • EPS Growth
  • NTLA N/A
  • AMRC 9.21
  • EPS
  • NTLA N/A
  • AMRC 1.17
  • Revenue
  • NTLA $52,857,000.00
  • AMRC $1,858,653,000.00
  • Revenue This Year
  • NTLA $9.20
  • AMRC $10.00
  • Revenue Next Year
  • NTLA N/A
  • AMRC $9.09
  • P/E Ratio
  • NTLA N/A
  • AMRC $33.56
  • Revenue Growth
  • NTLA 14.99
  • AMRC 22.85
  • 52 Week Low
  • NTLA $5.90
  • AMRC $8.49
  • 52 Week High
  • NTLA $26.99
  • AMRC $40.88
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 84.32
  • AMRC 77.22
  • Support Level
  • NTLA $19.89
  • AMRC $36.10
  • Resistance Level
  • NTLA $21.49
  • AMRC $38.00
  • Average True Range (ATR)
  • NTLA 1.73
  • AMRC 2.08
  • MACD
  • NTLA 0.71
  • AMRC 0.27
  • Stochastic Oscillator
  • NTLA 86.83
  • AMRC 85.19

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About AMRC Ameresco Inc.

Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.

Share on Social Networks: